Biotherapy of mice’s serum 13cH modifies parasitological and immunological parameters of Trypanosoma cruzi infection.

Authors

  • Fabiana Nabarro Ferraz Universidade Estadual de Maringá
  • Franciele Karina da Veiga Universidade Estadual de Maringá
  • Denise Lessa Aleixo Universidade Estadual de Maringá
  • Suelen Santos da Silva Universidade Estadual de Londrina
  • Wander Rogério Pavanelli Universidade Estadual de Londrina
  • Silvana Marques de Araújo Universidade Estadual de Maringá

Keywords:

Trypanosoma cruzi, high dilution, biotherapy, cytokines, parasitemia.

Abstract

Background: T. cruzi biotherapies’ alter the infection course by this protozoan [1,2], fact that encourages the evaluation of other highly diluted medicines which modulates host’s immune system. Aim: Evaluate effect of biotherapy produced from mices’s serum in experimental infection by T. cruzi. Methodology: A blind, randomized and controlled study was performed. Animals: 60 male Swiss mice, four weeks old were inoculated intraperitoneally with 1400 trypomastigotes-Y strain and divided: MNI: mice non-infected by T. cruzi; IC: treated with hydroalcoholic solution 7%; BSI13cH: treated with mice’s serum infected by T. cruzi 13cH. Biotherapies: produced from mice’s serum infected by T. cruzi in 13cH dynamization [3]. Treatment: mice were treated 48 hours before and after infection. Subsequently animals were treated 56/56 hours until 9th day of infection (d.i). The medicine was diluted in water (1/100mL) and offered ad libitum, for 16 hours. Parasitological parameters: were evaluated pre-patent and patent period, parasitemia peak, total parasitemia and mortality [4]. Cytokine dosage: IL-4, IL-17, TNF-α and IFN-γ were measured in serum on 0, 8th and 12th d.i., by enzyme immunoassay. Ethics: study was approved by Ethics Committee for Experiments in Animals/UEM. Statistic: data were compared with Mann Whitney or Student t test, significance 5%. Results: BSI13cH showed tendency to increase total parasitemia (p=0.06) and parasitemia peak (p=0.05), with lower patent period (p=0.03) and higher mortality (p=0.03) compared to IC. In dosage of cytokines BSI13cH group showed on 0 d.i. a decrease in IL-17 (p = 0.02) and increased IL-4 (p = 0.01) compared to MNI (baseline value), probably caused by modulation of medication administration 48 hours before infection. IL-17 concentration didn’t vary throughout the infection to BSI13cH, different IC that tended to decrease concentration of cytokine on 8th d.i. IL-4 increased significantly on 0 d.i. to BSI13cH, with subsequent return to baseline values. IC group didn’t change significantly IL-4 value along the infection. IFN-γ concentration on 12th d.i. to BSI13cH was lower (p = 0.00) than IC, which increased this cytokine on 8th and 12th di. TNF-α concentration of BSI13cH followed the same evolution as IC, with an increase on 8th and 12th d.i. (Figure 1). The medicine seems initially promote Th2 response (IL-4), hindering the development of effective Th1 response (INF-γ), causing an increase of parasitemia and animals' death. Conclusions: BSI13cH demonstrated effect in experimental infection by T. cruzi with increased parasitemia, animals’ premature death and modulated immune response differently of IC.

Author Biographies

Fabiana Nabarro Ferraz, Universidade Estadual de Maringá

Department of Basic Health Science/Sector Parasitology.

Franciele Karina da Veiga, Universidade Estadual de Maringá

Department of Basic Health Science/Sector Parasitology.

Denise Lessa Aleixo, Universidade Estadual de Maringá

Department of Basic Health Science/Sector Parasitology.

Suelen Santos da Silva, Universidade Estadual de Londrina

Department of Science Pathology

Wander Rogério Pavanelli, Universidade Estadual de Londrina

Department of Science Pathology

Silvana Marques de Araújo, Universidade Estadual de Maringá

Department of Basic Health Science/Sector Parasitology.

Downloads

Published

2014-05-15

Most read articles by the same author(s)

1 2 3 4 > >>